- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Interactive Options Course
Posted October 22, 2025 at 10:45 am
To write about and then invest in future trends implies a love of disruption. As the economist Josef Schumpeter noted, disruptive innovation is critical to progress. What better way to pass the time than attend a ‘disruptive tech’ conference? A skyscraper in the City of London served as the venue for panels and presentations from some of Europe’s most exciting (and mostly private) companies. Here are the key highlights.
The quantum computing discussion was by far the best attended event of the day. Your author was not surprised. We discussed in this year’s post #22 that if AI is the current hot topic in tech, quantum has the potential to be the next big thing. As one panellist put it, quantum processes can “enhance” AI. While the exact mechanisms are still emerging, the promise of optimisation and improved problem solving is tantalising. More practically, when quantum is applied to materials science, it may represent a “playground for engineers” and “revolutionise all industries.” A recent Bain report suggests the market potential for quantum could be between $100bn and $250bn.
The defence and space industries may be two that could benefit from quantum advances. Given the ongoing war on the edge of Europe, this session was also well-attended and the discussion lively. The key takeaway: governments need to be more proactive and pragmatic in their decision-making and embrace more technology. Procurement processes can and should be accelerated. We were also left in little doubt that space will potentially be the next battleground in warfare. As we discussed earlier this year, compromise satellites and you have a big problem. Mission-critical data such as geo-location may simply not be available.
Closer to home, technology is also poised to revolutionise the healthcare sector. Developing new drugs is both time-consuming and expensive, typically taking a decade and costing around $2bn. Fewer than 10% of candidate drugs make it to market. Healthcare is “becoming more of a data exercise,” we were told by one of the speakers at the event. AI technology can improve drug discovery rates and also make hospitals more efficient. However, as with any other technology, two challenges remain: scaling effectively and finding appropriate talent.
—
Originally Posted on October 22, 2025 – Everything disrupted everywhere
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!
The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.
The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital’s prior written consent.
Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email london@heptagon-capital.com
Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Heptagon Capital and is being posted with its permission. The views expressed in this material are solely those of the author and/or Heptagon Capital and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Related Articles
I have lost so much in the financial market and was really devastated, I almost gave up until I was directed to DENISE EXPERT RECOVERY. professional trader and their Recovery company and Foundation that helped me to recover 90% of the money I had lost. It was really worth it. I will be happy to share my experience with anybody, you can also connect with them for help and assistance for a successful and secured trading with consistent profits.